Spanish doctors and researchers say advances in multiple myeloma care have significantly extended patients’ lives, with some reaching functional remission. Event participants have described survival gains as threefold, although this is not a confirmed national average.
Spanish medical sources stress that multiple myeloma, while often managed as a chronic illness, is not yet curable for everyone. Some studies of new drug combinations show patients can go nearly twice as long without their disease worsening, and overall survival has improved. A universal cure remains out of reach. Spanish experts say the claim that survival has “tripled” reflects event participants’ views, not a confirmed national average. Strict validation would require published Spanish cohort data with clear definitions and breakdowns by age, treatment and time period.
The Spanish CAR-T therapy ARI-0002 received AEMPS approval in July 2024 for patients with relapsed multiple myeloma. Hospital Clínic de Barcelona produces and administers it under a special hospital exemption procedure.
This progress grew out of an unusual partnership between academic doctors and the pharmaceutical industry. Joaquín Martínez López, who leads Hematology and Hemotherapy at Hospital Universitario 12 de Octubre and teaches at Universidad Complutense de Madrid, credits the teamwork for the rapid advances. He says both sides shared knowledge and resources, even when money was tight and the future looked uncertain.
Jacobo Muñoz, medical director at Johnson & Johnson España, calls the change a revolution. He says the turning point came when doctors recognized multiple myeloma as a group of related conditions with different targets, not a single disease. That understanding opened the door to new treatments, including immunomodulators, monoclonal antibodies and CAR-T cell therapies. Spain’s public health system and skilled specialists have helped the country take a leading role. Spanish healthcare authorities report that access to CAR-T therapies is growing: 14 autonomous communities now offer advanced therapies, and more than 40 centers are accredited. The expansion reflects scientific progress alongside the infrastructure needed to deliver these treatments.
The path here was difficult. Martínez López recalls Spanish researchers having to stretch every euro, relying on what he calls “Spanish talent” to make things work with limited means. As results improved, government support grew, speeding the rollout of new therapies and enabling more patients to receive the latest care.
Independent Spanish medical sources say the public advanced-therapy model reduces logistical dependence on international manufacturers. ARI-0002 is produced in hospital clean rooms for local patients, avoiding international transport and related costs.
Companies like Johnson & Johnson now face a new challenge: working with patients, doctors and health officials to shorten the time it takes for new treatments to reach those who need them. The goal is to get innovations to patients as soon as possible, rather than years after a breakthrough.
Access is only half the battle. Muñoz credits Spanish doctors’ dedication and generosity, calling them a “bulwark” of progress. Their work collecting real-world data through federated databases that track thousands of patients has enabled studies reflecting what happens in clinics, beyond the controlled-trial setting. Such data help compare results across regions and develop lasting therapies. International studies show that median overall survival for myeloma patients rose from about 50.7 months in the 2000-2007 group to 72.5 months in the 2008-2015 group. For patients under 70 who received at least two modern induction drugs, median survival reached about 12 years, compared with 5.5 years with older treatments. These figures reflect global progress; specific Spanish data are still needed.
The focus is shifting to treatments that do not require lifelong use and let patients live as normally as possible. Martínez López says new therapies should disrupt daily life as little as possible. Muñoz hopes future drugs will produce stronger responses and target outcomes that matter most to patients. Treatment is also moving earlier: CAR-T and bispecific antibodies are now used for relapsed or refractory myeloma, while researchers are testing bispecific drugs for smoldering myeloma, aiming to eliminate even the smallest traces of disease.
Spain’s progress against multiple myeloma is part of a broader story. The country’s strong health system and scientific expertise have attracted international investment in research and development. Recent reports have highlighted pharmaceutical companies’ calls for faster access to the Spanish market.
Spain’s medical community is known for its grit and flexibility. Despite limited resources, Spanish doctors have taken a leading role on the world stage. Treatment advances have turned a once-dire diagnosis into one associated with hope and steady progress.
